Clinical Trials Logo

Surfactant clinical trials

View clinical trials related to Surfactant.

Filter by:
  • None
  • Page 1

NCT ID: NCT03479450 Recruiting - Surfactant Clinical Trials

Surfactant for Neonatal Respiratory Distress Syndrome at High Altitude Areas:a Prospective Cohort Study

Start date: March 1, 2020
Phase:
Study type: Observational

The traditional concept believes that the etiology of neonatal respiratory distress syndrome (RDS) is immature development of lung,especially the surfactant synthesis system,and RDS is still one of the major causes of mortality and morbidity in newborns, especially premature infants.In recent years, using pulmonary surfactant replacement therapy (PS treatment) in the treatment of respiratory distress syndrome (RDS) is a major breakthrough in neonatal medicine.Combined with clinical practice and experience,and through Meta analysis of related randomized controlled trials (RCTs),it confirms that natural surfactant treatment can reduce mortality,the incidence of pulmonary air leaks (pneumothorax and interstitial lung emphysema),and the incidence of bronchopulmonary dysplasia (BPD) or 28-day-old mortality.For RDS in preterm infants whose gestation is <35 weeks ,surfactant replacement therapy is also more effective than in nearly term and full term infants.Therefore, in the analysis of cases of different gestational age groups,the investigators should focus on the study of premature infants cases.Due to less relevant research for using PS treatment to cure newborn RDS in high altitude area,this retrospective study conducts statistics and analysis of recently three-year cases in some hospital of high altitude area,to explore the treatment effect of the high altitude region and the impact of altitude on the treatment.

NCT ID: NCT03440333 Completed - Surfactant Clinical Trials

Pulmonary Surfactant(PS) Therapy at High Altitude Area

Start date: January 1, 2015
Phase: N/A
Study type: Observational

The traditional concept believes that the etiology of neonatal respiratory distress syndrome (RDS) is immature development of lung,especially the surfactant synthesis system,and RDS is still one of the major causes of mortality and morbidity in newborns, especially premature infants[1].In recent years, using pulmonary surfactant replacement therapy (PS treatment) in the treatment of respiratory distress syndrome (RDS) is a major breakthrough in neonatal medicine [2].Combined with clinical practice and experience,and through Meta analysis of related randomized controlled trials (RCTs),it confirms that natural surfactant treatment can reduce mortality,the incidence of pulmonary air leaks (pneumothorax and interstitial lung emphysema),and the incidence of bronchopulmonary dysplasia (BPD) or 28-day-old mortality.For RDS in preterm infants whose gestation is <35 weeks ,surfactant replacement therapy is also more effective than in nearly term and full term infants.Therefore, in the analysis of cases of different gestational age groups,the investigators should focus on the study of premature infants cases.Due to less relevant research for using PS treatment to cure newborn RDS in high altitude area,this retrospective study conducts statistics and analysis of recently three-year cases in some hospital of high altitude area,to explore the treatment effect of the high altitude region and the impact of altitude on the treatment.

NCT ID: NCT03273764 Completed - Clinical trials for Respiratory Distress Syndrome in Premature Infant

Clinical RD (Respiratory Distress) Score for Objective Decision Making for Surfactant Therapy

Start date: January 1, 2015
Phase: N/A
Study type: Observational

To develop a comprehensive ʻClinical RD score' for decision making for administration of Surfactant in respiratory distress syndrome in preterm infants with gestation of 26 0/7 - 34 6/7 weeks and to assess the validity of this ʻclinical RD score' on a different subgroup of patients with similar gestational age.

NCT ID: NCT03217162 Recruiting - ARDS Clinical Trials

Surfactant for Neonate With Acute Respiratory Distress Syndrome (ARDS)

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Acute respiratory distress syndrome (ARDS) in neonates has been defined, the role of surfactant is not clear. This study aimed to determine whether ARDS neonate would benefit from surfactant when oxygenation deteriorated on mechanical ventilation and to identify any potential risk factors related to mortality.

NCT ID: NCT01265589 Not yet recruiting - Infant, Newborn Clinical Trials

Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome

RDS
Start date: January 2012
Phase: Phase 3
Study type: Interventional

To research the effect of vitamin A to newborn respiratory distress syndrome by intratracheal administration with surfactant.